Immunomodulatory Effects of Dexmedetomidine Infusion

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-01-01

Study Completion Date

2022-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Anesthetic management may affect both immunostimulatory and immunosuppressive mechanisms directly by modulating immune cell function or indirectly by attenuating the stress response, Thus, the choice of anesthetic technique may affect clinical outcomes by perturbing the balance between pro- and anti-inflammatory responses,anesthetics favoring this delicate balance are thus desirable as their use may reduce postoperative complications and mortality

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dexmedetomidine Combined With Lidocaine Infusion Affect Inflammation Cytokines

NCT03276533

Anesthesia; Reaction

COMPLETED NA

Immunomodulatory Effect of Dexmedetomidine as an Adjuvant Drug in Laparoscopic Cholecystectomies

NCT05489900

Physiological Effects of Drugs

UNKNOWN PHASE3

The Impact of a Dexmedetomidine Perfusion on Intraoperative Remifentanil Consumption

NCT06684197

Dexmedetomidine Total Intravenous Anesthesia Remifentanil Consumption +2 more

NOT_YET_RECRUITING NA

Efficacy and Safety of Dexmedetomidine in the Analgesic Prophylaxis , in Patients Undergoing Cardiovascular Surgery

NCT05079672

Cardiopathy Coronary Artery Disease Valve Heart Disease +1 more

UNKNOWN PHASE4

Dexmedetomidine in IVRA

NCT05123170

Regional Anesthesia Morbidity

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Abdominal Surgery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dexmedetomidine group

patients will receive a loading dose of IV Dexmedetomidine1μg/kg slowly just before induction of anesthesia, then Dexmedetomidine infusion started at a rate of 0.5μg/kg/h.

Group Type ACTIVE_COMPARATOR

Dexmedetomidine

Intervention Type DRUG

patients will receive a loading dose of IV Dexmedetomidine1μg/kg slowly just before induction of anesthesia, then Dexmedetomidine infusion started at a rate of 0.5μg/kg/h.

Control group

patients will receive an equal volume of 0.9% sodium chloride (both the loading, and the infusion

Group Type PLACEBO_COMPARATOR

0.9% sodium chloride

Intervention Type DRUG

patients will receive an equal volume of 0.9% sodium chloride (both the loading, and the infusion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dexmedetomidine

patients will receive a loading dose of IV Dexmedetomidine1μg/kg slowly just before induction of anesthesia, then Dexmedetomidine infusion started at a rate of 0.5μg/kg/h.

Intervention Type DRUG

0.9% sodium chloride

patients will receive an equal volume of 0.9% sodium chloride (both the loading, and the infusion

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* scheduled for elective laparoscopic major abdominal surgeries;
* ASA class II-III

Exclusion Criteria

\- 1- Patients with severe infection or diseases in respiratory system 2- Patients with severe arrhythmia or bradycardia 3- Patients with severe diseases in liver, kidney, endocrine or immune system. 4- Patients with history of uncontrolled hypertension, A-V conduction block. 5- Patients who had administrated the α-adrenergic agonists or β-receptor antagonist.

6- Patients who received the chemotherapy, radiotherapy, or immunotherapy within one month before operation 7- Patients who had feverbefore operation

Minimum Eligible Age

25 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No